Axol Bioscience offers cardiomyocytes that are extracted only from human iPSCs. The company does not utilize any embryonic stem cells (ESCs) or animal cells.
Axol Bioscience provides quality cells that deliver consistent results. It is a brand that users can trust.
Human iPSC-derived atrial cardiomyocytes from Axol Bioscience contain one million cells per vial.
Description
The atrial-specific markers atrial natriuretic peptide (ANP) and atrial myosin light chain 2 (MLC2a) are expressed by Axol iPSC-derived atrial cardiomyocytes. Atrial cardiomyocytes are crucial for studying atrial fibrillation like irregular heart rate; hence, they are highly suitable for disease modeling.
Axol Bioscience’s iPSC-derived atrial cardiomyocytes have been extracted from the same newborn male donor as the company’s iPSC-derived ventricular cardiomyocytes that are highly validated.
Axol iPSC-derived cardiomyocytes and serum-free, fully defined cardiomyocyte maintenance medium provide scientists with a complete range of complementary culture reagents and cell types for cardiotoxicity testing and disease modeling.
Product Specification
| . |
. |
| Starting material |
Cord blood CD34+ cells |
| Donor gender |
Male |
| Donor age at sampling |
Newborn |
| HLA serotype |
A29 A68, B38(Bw4) B44(Bw4), Cw8 Cw12 |
| Karyotype |
Normal |
| Reprogramming method |
Episomal vector |
| Induction method |
Monolayer & chemically defined medium |
| Genetic modification |
None |
| Size |
1 million cells |
| Growth properties |
Adherent |
| Shipping conditions |
Dry ice |
| Storage conditions |
vapour phase nitrogen |